Heart Care Info - Heart Disease Prevention & Treatment

Endothelin‐2, the Forgotten Isoform: Emerging Role in the Cardiovascular System, Ovarian Development, Immunology and Cancer

L Ling, JJ Maguire... - British Journal of ..., 2011 - Wiley Online Library Summary Endothelin-2 (ET-2, also known as vasoactive intestinal contractor or VIC, in rodents) differs from endothelin-1 (ET-1) by only two amino acids, and unlike the third isoform, endothelin-3 (ET-3), it has the same affinity as ET-1 for both ET A and ET B ... [HTML]

Endothelin 2 (ET 2, also known as vasoactive intestinal contractor or VIC, in rodents) differs from endothelin 1 (ET 1) by only two amino acids, and unlike the third isoform, endothelin 3 (ET 3), it has the same affinity as ET 1 for both ETA and ETB receptors. It is often assumed that ET 2 would mimic the actions of the more abundant ET 1 and current pharmacological interventions used to inhibit the ET system would also block the actions of ET 2. These assumptions have focused research on ET 1 with ET 2 studied in much less detail. Recent research suggests that our understanding of the ET family requires re evaluation. Although ET 2 is very similar in structure as well as pharmacology to ET 1, and may co exist in the same tissue compartments, there is converging evidence for an important and distinct ET 2 pathway. Specifically is has been demonstrated that ET 2 has a key role in ovarian physiology, with ET 2 mediated contraction proposed as a final signal facilitating ovulation. Furthermore, ET 2 may also have a pathophysiological role in heart failure, immunology and cancer. Comparison of ET 2 versus ET 1 m RNA expression suggests this may be accomplished at the level of gene expression but differences may also exist in peptide synthesis by enzymes such as endothelin converting enzymes (ECE) and chymase which may allow the two pathways to be distinguished pharmacologically and become separate drug targets.